8-K: Patterson Companies Reports Lower Q3 Earnings Amidst Pending Acquisition

Patterson Companies' Q3 fiscal 2025 results reveal a decrease in net sales and earnings, impacted by market challenges and a cybersecurity attack, as the company progresses towards its acquisition by Patient Square Capital.

Summary

• Patterson Companies reported a 2.7% year-over-year decrease in net sales for the third quarter of fiscal year 2025, totaling $1.57 billion.
• Internal sales decreased by 2.4% compared to the same period last year.
• GAAP earnings were $0.35 per diluted share, while adjusted earnings were $0.43 per diluted share, both negatively impacted by the Change Healthcare cybersecurity attack.
• The company returned $119.2 million to shareholders through dividends and share repurchases in the first nine months of fiscal 2025.
• Net income attributable to Patterson Companies was $31.3 million, or $0.35 per diluted share, compared to $47.7 million, or $0.52 per diluted share, in the third quarter of fiscal 2024.
• Adjusted net income was $38.7 million, or $0.43 per diluted share, compared to $55.0 million, or $0.59 per diluted share, in the third quarter of fiscal 2024.
• Dental segment net sales were $596.3 million, with internal sales decreasing by 6.0%.
• Animal Health segment net sales were $972.4 million, with internal sales increasing by 0.2%.
• The company used $735.1 million of cash from operating activities during the first nine months of fiscal 2025.
• Free cash flow declined by $49.6 million compared to the first nine months of fiscal 2024.
• Consolidated net sales for the first nine months of fiscal 2025 totaled $4.79 billion, a 1.2% year-over-year decrease.
• The company is set to be acquired by Patient Square Capital for $31.35 per share in an all-cash transaction valued at approximately $4.1 billion, expected to close in April 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral due to the mixed results and the pending acquisition. While sales and earnings are down, the acquisition provides a positive exit for shareholders. The cybersecurity incident and market challenges temper any strong positive outlook.

Positives

• The Animal Health segment showed resilience with a 0.2% increase in internal sales for the third quarter.
• Value-added services in the Animal Health segment increased by 10.8% in internal sales for the third quarter.
• The company returned significant capital to shareholders, totaling $119.2 million in the first nine months of fiscal 2025.
• The pending acquisition by Patient Square Capital provides shareholders with a cash value of $31.35 per share.

Negatives

• Net sales decreased by 2.7% year-over-year to $1.57 billion for the third quarter of fiscal 2025.
• Internal sales decreased by 2.4% compared to the same period last year.
• The Dental segment experienced a 6.0% decrease in internal sales for the third quarter.
• GAAP and adjusted earnings were negatively impacted by the cybersecurity attack on Change Healthcare.
• Free cash flow declined by $49.6 million compared to the first nine months of fiscal 2024.

Risks

• The pending acquisition is subject to customary closing conditions, including shareholder and regulatory approvals, which may not be obtained.
• The cybersecurity attack on Change Healthcare negatively impacted the value-added services category of the dental segment.
• The company faces risks associated with dependence on suppliers, distribution capabilities, and relationships with sales representatives.
• The company is exposed to risks inherent in the health care industry, including changes in demand due to political, economic, and regulatory influences.
• The company faces risks related to climate change and uncertain macro-economic conditions, including inflationary pressures.

Future Outlook

In light of the pending acquisition by Patient Square Capital, Patterson will not be providing an update to forward-looking earnings guidance and will not conduct a quarterly earnings call.

Management Comments

• As we continue to progress toward closing our transaction with Patient Square Capital, our team remains focused on executing our strategy, said Don Zurbay, President and CEO of Patterson Companies.
• While our third quarter results were impacted by challenging market conditions, we remain confident in the long-term strength of Pattersons value proposition as an indispensable partner to customers across the durable and attractive dental and animal health end markets.

Industry Context

Patterson Companies operates in the competitive dental and animal health supply markets, facing challenges from consolidation, GPOs, and changing consumer demands. The cybersecurity attack on Change Healthcare highlights the increasing risks associated with technology and data security in the healthcare industry.

Comparison to Industry Standards

• Without specific competitor data in this document, a detailed comparison to industry standards is limited.
• However, the decline in dental consumables and equipment sales suggests Patterson is underperforming compared to broader market trends, especially considering companies like Henry Schein and Benco Dental are key players.
• The animal health segment's slight growth contrasts with companies like Zoetis and Elanco, which have shown more robust growth in the animal health market.
• The impact of the Change Healthcare cybersecurity attack is a unique event, making direct comparisons difficult, but it underscores the importance of robust cybersecurity measures, similar to those emphasized by McKesson and Cardinal Health.

Stakeholder Impact

• Shareholders will receive $31.35 per share in cash upon completion of the acquisition.
• Employees face uncertainty regarding their roles and the future direction of the company post-acquisition.
• Customers may experience changes in service and product offerings as the company transitions to private ownership.
• Suppliers may need to adjust to new management and operational strategies under Patient Square Capital.

Next Steps

• The company will focus on completing the acquisition by Patient Square Capital, expected to close in April 2025.

Key Dates